PI3K protein inhibitor has great therapeutic effect for PanNET

Recently, researchers from Bellvitge Institute for Biomedical Research found an inhibitor of PI3K protein has a good therapeutic effect in pancreatic neuroendocrine tumors (PanNET). The study was published in the journal Clinical Cancer Research. More studies about recombinant proteins like recombinant dog proteins and recombinant horse proteins can be found in it. The research results greatly enhanced scientists' understanding of the role of PI3K signaling pathway in cancer and provide a new way for pancreatic endocrine tumor treatment of neurological and other tumors.

Pancreatic neuroendocrine tumor is also called islet cell tumors, and this type of pancreatic cancer accounts for about 2% of all newly diagnosed cases of pancreatic cancer. In the past 20 years, almost no better ways to treat this type of cancer, and PanNET heterogeneity also make the design of targeted therapies very complicated. Research shows that 16 percent of PanNET patients carrying mutations of PI3K signaling pathway and the researchers evaluated the activity of PI3K pathway tumor of samples of 40 cases.

The researchers found that no matter by genetic means or by means of pharmacological inhibition of specific PI3K isoform (also known as p110α), the effects all are sufficient to induce tumor cell death and inhibiting angiogenesis, thereby preventing tumor progression and metastasis. Compared with general inhibitors, this inhibitor with configuration specificity has a lower the toxicity to human body. The human body can accept higher doses to achieve the role of complete closure of PI3K signaling pathway.

PI3K inhibitors have been used in clinical practice. These findings all indicated that this new inhibitor is promising to become the treatment way of this vicious disease. The study also reveals new role of PI3K protein in cancer biology with the use of recombinant Cdh1.